Table 4

Multivariate analyses of leukemia-free survival, treatment-related mortality, and relapse in patients transplanted for first chronic phase

VariablenRelative risk of death (95% CI)P
Leukemia-free survival 
    Main effect 
    No imatinib 657 1.00*  
    Imatinib 181 0.89 (0.68- 1.15) .36† 
    Other significant covariates 
    GVHD prophylaxis   < .001‡ 
    MTX + CsA ± others 537 1.00*  
    T-cell depletion 59 1.96 (1.40-2.76) < .001 
    FK506 + MTX ± others 130 1.15 (0.86-1.55) .340 
    FK506 ± others 19 2.60 (1.45-4.67) .001 
    CsA ± others 93 1.58 (1.15-2.15) .004 
    Time from diagnosis to transplantation 
    ≤ 12 mo 516 1.00  
    > 12 mo 322 1.56 (1.27-1.93) < .001† 
Treatment-related mortality 
    Main effect 
    No imatinib 657 1.00*  
    Imatinib 181 0.70 (0.49- 0.98) .040† 
    Other significant covariates 
    Donor-recipient HLA match   < .001‡ 
    Matched sibling 327 1.00*  
    Well matched 217 1.36 (0.96-1.93) .080 
    Partially matched 160 1.74 (1.24-2.44) .001 
    Mismatch 92 2.40 (1.65-3.47) < .001 
    Unknown 42 1.78 (1.01-3.16) .048 
    Time from diagnosis to transplantation 
    ≤ 12 mo 516 1.00  
    > 12 mo 322 1.54 (1.20-1.99) < .001† 
Relapse§ 
    Main effect 
    No imatinib 657 1.00*  
    Imatinib 181 1.54 (1.02-2.35) .041† 
    Other significant covariates 
    GVHD prophylaxis   .004‡ 
    MTX + CsA ± others 537 1.00*  
    T-cell depletion 59 2.67 (1.50-4.76) < .001 
    FK506 + MTX ± others 130 1.08 (0.63-1.85) .790 
    FK506 ± others 19 2.66 (1.10-6.46) .031 
    CsA ± others 93 1.66 (0.94-2.95) .083 
VariablenRelative risk of death (95% CI)P
Leukemia-free survival 
    Main effect 
    No imatinib 657 1.00*  
    Imatinib 181 0.89 (0.68- 1.15) .36† 
    Other significant covariates 
    GVHD prophylaxis   < .001‡ 
    MTX + CsA ± others 537 1.00*  
    T-cell depletion 59 1.96 (1.40-2.76) < .001 
    FK506 + MTX ± others 130 1.15 (0.86-1.55) .340 
    FK506 ± others 19 2.60 (1.45-4.67) .001 
    CsA ± others 93 1.58 (1.15-2.15) .004 
    Time from diagnosis to transplantation 
    ≤ 12 mo 516 1.00  
    > 12 mo 322 1.56 (1.27-1.93) < .001† 
Treatment-related mortality 
    Main effect 
    No imatinib 657 1.00*  
    Imatinib 181 0.70 (0.49- 0.98) .040† 
    Other significant covariates 
    Donor-recipient HLA match   < .001‡ 
    Matched sibling 327 1.00*  
    Well matched 217 1.36 (0.96-1.93) .080 
    Partially matched 160 1.74 (1.24-2.44) .001 
    Mismatch 92 2.40 (1.65-3.47) < .001 
    Unknown 42 1.78 (1.01-3.16) .048 
    Time from diagnosis to transplantation 
    ≤ 12 mo 516 1.00  
    > 12 mo 322 1.54 (1.20-1.99) < .001† 
Relapse§ 
    Main effect 
    No imatinib 657 1.00*  
    Imatinib 181 1.54 (1.02-2.35) .041† 
    Other significant covariates 
    GVHD prophylaxis   .004‡ 
    MTX + CsA ± others 537 1.00*  
    T-cell depletion 59 2.67 (1.50-4.76) < .001 
    FK506 + MTX ± others 130 1.08 (0.63-1.85) .790 
    FK506 ± others 19 2.66 (1.10-6.46) .031 
    CsA ± others 93 1.66 (0.94-2.95) .083 

CI indicates confidence interval.

*

Reference group.

†

One degree of freedom.

‡

Four degrees of freedom.

§

Stratified on conditioning regimen because of nonproportional hazards.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal